We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
In the latest trading session, Johnson & Johnson (JNJ - Free Report) closed at $157.69, marking a -1.6% move from the previous day. This change lagged the S&P 500's 0.24% loss on the day.
Prior to today's trading, shares of the world's biggest maker of health care products had lost 3.35% over the past month. This has was narrower than the Medical sector's loss of 6.43% and lagged the S&P 500's loss of 2.12% in that time.
Wall Street will be looking for positivity from JNJ as it approaches its next earnings report date. This is expected to be October 19, 2021. The company is expected to report EPS of $2.37, up 7.73% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $23.62 billion, up 12.05% from the year-ago period.
JNJ's full-year Zacks Consensus Estimates are calling for earnings of $9.65 per share and revenue of $94.24 billion. These results would represent year-over-year changes of +20.17% and +14.12%, respectively.
Investors might also notice recent changes to analyst estimates for JNJ. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.01% lower within the past month. JNJ is holding a Zacks Rank of #4 (Sell) right now.
Digging into valuation, JNJ currently has a Forward P/E ratio of 16.6. For comparison, its industry has an average Forward P/E of 13.35, which means JNJ is trading at a premium to the group.
It is also worth noting that JNJ currently has a PEG ratio of 2.14. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.05 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 102, which puts it in the top 41% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow JNJ in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should Know
In the latest trading session, Johnson & Johnson (JNJ - Free Report) closed at $157.69, marking a -1.6% move from the previous day. This change lagged the S&P 500's 0.24% loss on the day.
Prior to today's trading, shares of the world's biggest maker of health care products had lost 3.35% over the past month. This has was narrower than the Medical sector's loss of 6.43% and lagged the S&P 500's loss of 2.12% in that time.
Wall Street will be looking for positivity from JNJ as it approaches its next earnings report date. This is expected to be October 19, 2021. The company is expected to report EPS of $2.37, up 7.73% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $23.62 billion, up 12.05% from the year-ago period.
JNJ's full-year Zacks Consensus Estimates are calling for earnings of $9.65 per share and revenue of $94.24 billion. These results would represent year-over-year changes of +20.17% and +14.12%, respectively.
Investors might also notice recent changes to analyst estimates for JNJ. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.01% lower within the past month. JNJ is holding a Zacks Rank of #4 (Sell) right now.
Digging into valuation, JNJ currently has a Forward P/E ratio of 16.6. For comparison, its industry has an average Forward P/E of 13.35, which means JNJ is trading at a premium to the group.
It is also worth noting that JNJ currently has a PEG ratio of 2.14. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.05 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 102, which puts it in the top 41% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow JNJ in the coming trading sessions, be sure to utilize Zacks.com.